Gyrolab Spin Blog: matrix

Feb 19, 2020 4:31:53 PM

Solutions to immunoassay interference, cross reactivity and other challenges

Solutions to immunoassay interference, cross reactivity and other challengesImmunoassays have become invaluable in the generation of data for preclinical and clinical studies, process development/optimization and manufacture of biotherapeutics, and also for new applications such as determining viral titer in cell and gene therapy. Having confidence in the data based on the accurate and precise determination of analytes in complex matrices means overcoming many challenges. These can include interference that reduces robustness, selectivity and specificity, the poor performance of cross-reacting antibody reagents, and time-consuming methods that threaten time plans. Such challenges can be overcome by choosing the right reagents, using the right approach on the right immunoassay platform to deliver reliable data as quickly as possible.

Read More

Topics: Matrix, Immunoassay


Apr 25, 2018 2:22:39 PM

How to overcome disease-specific matrix interference

Minimize incubation times with flow-through immunoassays

dropMatrix interference can be a major challenge in the development of immunoassays to study a number of disease states. Kathi Williams and her colleagues at Genentech Inc., USA, experienced considerable problems with matrix interference when developing an ELISA for Phase III studies of a humanized monoclonal antibody when a new patient group was introduced. The solution was to transfer the assay to the Gyrolab platform that, thanks to its flow-through technology helped minimizing matrix effects by reducing the incubation times with the capture reagent antibody.

Read More

Topics: Matrix, Pharmacokinetics, Immunoassay, Clinical trial, Phase III studies, Ulcerative colitis, Crohn's disease


Mar 3, 2016 10:59:00 AM

Find the flow and solve matrix interference problems

Gyros’ technology overcomes matrix effects in a Phase III PK assay

case_study2016.pngIt is not unusual for a pharmacokinetics assay used early on in a study proves to lack the robustness needed to see the drug candidate through to more advanced clinical studies. A team at Genentech experienced just that and they solved the problem by transferring their ELISA to the Gyrolab platform.

 

Read More

Topics: Matrix, Pharmacokinetics, Gyros


Jul 27, 2015 8:58:57 AM

The small, the rare, and the complex

Analyzing challenging matrices

dropWhile many preclinical and clinical studies require analysis of plasma, serum or blood, some involve more challenging matrices, such as vitreous and aqueous humor, tears, synovial fluid, and bronchoalveolar lavage. These matrices often have high viscosity, high protein concentration and low analyte concentration. Added to that, the samples are almost invariably very small, expensive and difficult to source. Analytical methods must therefore match the matrix’s complex qualities and also the small volumes available. 

 

Read More

Topics: Matrix, Microsampling


Jun 19, 2014 8:46:00 AM

AAPS awards poster prize for study of matrix effects using Gyrolab

award-ribbon-blueGyros technology wins for the third year in a row

The 2014 AAPS Biomarkers Best Abstract Award at the AAPS National Biotechnology Conference (May 19–21, San Diego, USA) has been awarded to Chase Shen and Chris Stebbins of Biogen Idec, Inc. for their poster reporting studies of matrix effects using Gyrolab, ’Urine Urea Impacts the Accuracy of Soluble Vascular Cell Adhesion Molecule 1 (sVCAM-1) Urinary Immunoassay’. Congratulations to Chase Shen and Chris Stebbins!

Read More

Topics: Biomarkers, Matrix